Back to search results

Progesterone Supplementation for Adolescents with Turner Syndrome

This study is looking at how different ways of taking progesterone affect bleeding patterns in adolescent girls (ages 12-20) with Turner Syndrome and primary ovarian insufficiency (POI). POI means their ovaries aren't working as they should. Participants are already taking estrogen replacement therapy. The study compares two ways of taking micronized progesterone: either 200mg for the first 12 days of a cycle, or 100mg daily throughout the cycle. Researchers will track menstrual bleeding patterns using a special chart for about 90 days to see which method works best. This study aims to help improve hormone replacement therapy for girls with Turner Syndrome.

Study design
This is a single-site, open-label study, meaning both you and the study team will know which treatment you are receiving. It is not randomized, and plans to include 40 participants.
What's involved
You would take either micronized progesterone 200mg for 12 days of a cycle or micronized progesterone 100mg daily throughout a cycle. Your menstrual bleeding patterns will be assessed for about 90 days.
Compensation
Not stated in the trial record.
Follow-up
Your menstrual bleeding patterns will be assessed from enrollment to the end of treatment at day 90.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06834594

Bleeding Patterns in Sequential and Continuous Progesterone Supplementation in Adolescents With Turner Syndrome

Recruiting
PHASE4Ages 12–20InterventionalTreatment
Children's Mercy Hospital Kansas City
~40 participants
Updated 2026-08-25 on ClinicalTrials.gov
What's tested:Micronized progesterone 200 MGMicronized Progesterone 100 MG

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Menstrual bleeding patterns as assessed by the Pictorial Bleeding Assessment Chart (PBAC)
Measured over From enrollment to end of treatment at day 90.

Conditions

Turner Syndrome
Primary Ovarian Insufficiency (Poi)

Explore related trials

Primary Ovarian FailureTurner Syndrome

Where it's being run

1 sites across 1 states
Missouri1

Study leadership

  • Tazim Dowlut-McElroy, M.D., M.S. · PRINCIPAL_INVESTIGATOR · Children's Mercy Kansas City

Who to contact

Allie Ranallo
[email protected]
+1-816-394-7534
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Diagnosis of Turner Syndrome and Primary Ovarian Insufficiency.
Prescribed adult dosing\* of transdermal or oral estradiol for estrogen replacement therapy.
Have achieved menarche.

Exclusion

Disclosure of sexual activity and desire for contraception.
Having a levonorgestrel-releasing intrauterine device or etonogestrel arm implant in place.
Having received depot medroxyprogesterone within one year prior to study recruitment.
Non-English or non-Spanish speaking.

What this trial measures

  • Menstrual bleeding patterns as assessed by the Pictorial Bleeding Assessment Chart (PBAC)From enrollment to end of treatment at day 90.

    PBAC is one of the most common scoring systems used in the literature to quantify menstrual blood loss (MBL) using a pictorial scoring system, with a higher score representing a larger MBL and a score \>100 qualifying as heavy menstrual bleeding